Work at Vivozon Inc. has led to the identification of dual metabotropic glutamate mGlu5 receptor antagonists and histone deacetylase 6 (HDAC6) inhibitors.

Pantetheinase (Vanin-1) inhibitors are described in an Athos Therapeutics Inc. patent as potentially useful for the treatment of autoimmune disease, cancer and inflammatory disorders.

University of Miami has patented new vasopressin V1A receptor antagonists reported to be useful for the treatment of osteoporosis, Paget disease and cancer.

Haisco Pharmaceutical Group Co. Ltd. has disclosed new tetrahydrofuran derivatives acting as sodium channel protein type 10 subunit alpha (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Ono Pharmaceutical Co. Ltd. has patented tricyclic prostaglandin E2 receptor EP3 subtype (PTGER3; EP3) agonists potentially useful for the treatment of renal diseases.

Work at Reactive Biosciences Inc. has led to the discovery of new phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.

A D3 Bio (Wuxi) Co. Ltd. patent describes heterocyclic-substituted pyrimidopyran compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Chengdu Zeling Biomedical Technology Co. Ltd. has identified triazine compounds acting as NLRP3 inflammasome inhibitors.

Southern Research Institute and UAB Research Foundation have jointly described pyrazolopyrimidines acting as bromodomain-containing protein 4 (BRD4; HUNK1) and/or receptor-interacting serine/threonine-protein kinase 3 (RIPK3) and/or interleukin-6 (IL-6) inhibitors.

Atai Therapeutics Inc. has identified 3-alkylamine indole compounds acting as 5-HT2A receptor agonists and reported to be potentially useful for the treatment of anxiety, eating and neurological disorders.